英派斯(002899) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥324,414,767.05, representing a 23.16% increase compared to the same period last year[2] - Net profit attributable to shareholders was ¥36,149,275.61, a 1.62% increase year-over-year, while the net profit excluding non-recurring items was ¥33,892,028.26, down 3.36%[2] - Year-to-date revenue as of Q3 2024 totaled ¥896,244,105.47, marking a 36.09% increase compared to the same period last year[2] - Revenue for the first nine months of 2024 reached CNY 896.24 million, a 36.09% increase compared to CNY 658.56 million in the same period of 2023, primarily driven by increased product sales[6] - Total operating revenue for the current period reached ¥896,244,105.47, a 36.1% increase from ¥658,560,464.41 in the previous period[20] - Net profit for the current period was ¥87,313,822.55, representing a 20.2% increase compared to ¥72,653,569.09 in the previous period[21] Assets and Liabilities - The company's total assets increased to ¥2,958,931,522.83, a growth of 28.94% from the end of the previous year[2] - The company's total liabilities increased to ¥1,276,965,616.50 from ¥1,054,059,193.02, reflecting a rise of approximately 21%[18] - Shareholders' equity rose to ¥1,681,965,906.33, reflecting a 35.56% increase compared to the end of the previous year[2] - The equity attributable to the parent company increased to ¥1,681,965,906.33 from ¥1,240,736,960.49, showing an increase of around 35.6%[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥77,904,154.25, showing a significant decline of 56.84% year-over-year[2] - The company reported a net cash flow from investing activities for Q3 2024 was -273,569,137.49, a decrease of 308.44% compared to -66,979,638.30 in Q3 2023[8] - The net cash flow from financing activities for Q3 2024 was -7,344,147.28, an improvement of 90.21% compared to -75,001,905.99 in Q3 2023[8] - Cash flow from operating activities generated ¥77,904,154.25, a decrease of 56.9% from ¥180,506,949.21 in the previous period[22] - Cash inflow from investment activities was ¥629,449,713.71, compared to ¥497,434,686.71 in the previous period, indicating a significant increase[22] - Cash inflow from financing activities totaled CNY 463,099,996.64, compared to CNY 150,000,000.00 in the previous period, indicating a significant increase[23] Expenses - Operating costs increased by 35.83% to CNY 612.15 million, up from CNY 450.67 million, reflecting the rise in sales-related costs[6] - Total operating costs increased to ¥779,086,616.93, up 39.7% from ¥557,287,883.43 in the previous period[20] - Research and development expenses rose to ¥36,475,962.32, an increase of 27.4% from ¥28,647,208.15 in the previous period[20] - Sales expenses increased to ¥51,752,052.24, up from ¥44,919,216.06 in the previous period, reflecting a growth of 15.9%[20] Shareholder Information - The top shareholder, Hainan Jiangheng Industrial Investment Co., Ltd., holds 27.51% of the shares, totaling 40,662,000 shares[9] - The second largest shareholder, Shenzhen Century Zhiyuan Private Securities Fund Management Co., Ltd., holds 2.44% of the shares, totaling 3,599,712 shares[9] - The total number of common shareholders at the end of the reporting period was 9,908[9] Other Financial Metrics - The company reported a basic earnings per share of ¥0.27, down 10.00% from the previous year[2] - The weighted average return on equity was 2.66%, a decrease of 0.29% compared to the previous year[2] - The company reported a significant increase in trading financial assets, which rose by 264.92% to ¥390,011,214.04 due to increased investment in financial products[4] - The company reported a significant increase in accounts receivable, which rose to ¥209,307,917.44 from ¥108,668,089.35, a growth of about 92.5%[17] New Developments - The company established a new subsidiary, Shanghai Yingpais Health Technology Co., Ltd., which is not expected to significantly impact overall operations and performance[15] - The company completed the replacement of self-raised funds with raised funds amounting to ¥382,345,279.66 for pre-invested projects and issuance costs[16] - The report indicates the first-time implementation of new accounting standards starting in 2024[23] Impairment and Tax - The credit impairment loss decreased by 63.48% to 1,597,271.09 from 4,373,712.21 in the previous period[8] - The asset impairment loss increased by 268.82% to 2,924,856.03 from -1,732,521.68 in the previous period[8] - The income tax expense decreased by 40.16% to 3,376,448.65 from 5,642,714.15 in the previous period[8]